Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
ZNTL - Zentalis Pharmaceuticals, Inc.
Market Cap 1.84B P/E - EPS this Y 32.90% Ern Qtrly Grth -
Income -194.65M Forward P/E -5.92 EPS next Y -19.00% 50D Avg Chg -3.00%
Sales 40.56M PEG - EPS past 5Y - 200D Avg Chg 16.00%
Dividend N/A Price/Book 4.03 EPS next 5Y - 52W High Chg -19.00%
Recommedations 2.30 Quick Ratio 6.39 Shares Outstanding 71.11M 52W Low Chg 68.00%
Insider Own 3.48% ROA -24.77% Shares Float 50.96M Beta 1.70
Inst Own 108.15% ROE -42.99% Shares Shorted/Prior 11.70M/11.57M Price 26.11
Gross Margin 100.00% Profit Margin - Avg. Volume 910,122 Target Price 9.90
Oper. Margin -543.77% Earnings Date Nov 4 Volume 433,924 Change -0.53%
Healthcare | Biotechnology | United States
About Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

Zentalis Pharmaceuticals, Inc. News
11/13/24 Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of Azenosertib
11/01/24 Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/21/24 Undervalued Opportunities: US Penny Stocks To Watch In October 2024
10/18/24 State Street Corp's Strategic Reduction in Zentalis Pharmaceuticals Holdings
10/15/24 Several Insiders Invested In Zentalis Pharmaceuticals Flagging Positive News
10/07/24 FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc
09/19/24 Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates
09/17/24 FDA lifts partial clinical hold on Zentalis Pharma’s cancer WEE1 inhibitor
09/17/24 Zentalis Stock Up as FDA Lifts Partial Hold on Cancer Drug Studies
09/16/24 FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers
09/16/24 Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies
09/09/24 Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024
08/26/24 Zentalis (ZNTL) Plunges More Than 70% in 3 Months: Here's Why
08/09/24 Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Progress
06/20/24 Biotech Stock Roundup: ITCI Up on Study Data, ZNTL, OVID Down on Updates & More News
06/19/24 Zentalis (ZNTL) Tanks After FDA Puts 3 Cancer Studies on Hold
06/19/24 FDA places partial clinical hold on Zentalis’ trials of azenosertib for cancer
06/18/24 US Equity Markets Close Up Tuesday Following Less-Than-Expected Retail Sales Growth
06/18/24 Top Midday Decliners
06/18/24 Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program
ZNTL Chatroom

User Image cta7978 Posted - 9 hours ago

$ZNTL OK, good they are now back to "recruiting" for the TETON: Phase 2 Monotherapy Study in Uterine Serous Carcinoma (updated yesterday). No update yet for the second arm for the Denali trial.

User Image cta7978 Posted - 11 hours ago

$ZNTL Pump n dump today

User Image cta7978 Posted - 1 day ago

$ZNTL Should probably dump this and come back after the first of the year. Dec seems to be looking like tax loss selling and short manipuation. Catalysts are in January, unless management lied again and they delay even further.

User Image Night_Owl_Biotech Posted - 3 days ago

$STRO is off 40% the last 7 trading days. This is the largest drop of 25 peer clinical-stage oncology focused bios with market caps between $150 & $650MM (see attachment). STRO's enterprise value (market cap - cash) = -$167MM. STRO is running a potential reg'l trial in certain ovarian cancers not suited for Elahere & has engaged a banker (Lazard) to find a long-term partner. Put simplest, it is worth investors efforts to fully research STRO as, though of course STRO could fail, its risk/reward profile is compelling again (especially if you believe stocks like STRO trade in cycles) Other clinical-stage oncology focused bios trading for well less than cash with near-term pot'l value inflection points/data reads incl $CMPX $ITOS & $ZNTL $BDTX trades slightly higher than cash but expects a Phase 2 data read in certain lung cancers in Q125 (BDTX's therapy was deemed "de-risked" by Piper Sandler after an interim read 2 months ago). This is not investment advice.

User Image zamun Posted - 3 days ago

$ZNTL what happened here, it was running up, now back down, buy the dip?

User Image cta7978 Posted - 3 days ago

$ZNTL just about everything recovering today except Zentalis.. why no PR stating trial enrollment pauses lifted? Why was the CEO canned? Smells like hot garbage. They scrapping the monotherapy due to the deaths?

User Image Sillyspuh Posted - 3 days ago

$ZNTL In October of 2019, Trillium stock goes down to .30. By October of 2020, it would be trading in the 20's (70x-80x). Zentalis just brought on two people who worked at Trillium.

User Image cta7978 Posted - 4 days ago

$ZNTL Management and their veil of secrecy, postponement of clinical updates, have sentenced us to likely all of December under $3.00

User Image Sillyspuh Posted - 4 days ago

$ZNTL Sales of PARP inhibitors (like lynparza) are expected to be at around $8B this year, growing to $20B+ by 2031. For believers in Zentalis' Azenosertib, they are hoping Wee1 inhibitors will be used like PARP inhibitors in the future-- given almost indiscriminately like candy alongside other treatments, because they are so likely to improve outcomes.

User Image cta7978 Posted - 4 days ago

$ZNTL If it goes below $3, it's retesting $2.66

User Image cta7978 Posted - 4 days ago

$ZNTL Backing up the truck on this one..

User Image cta7978 Posted - 4 days ago

$ZNTL OK one more to express my extreme dissatisfaction with management

User Image cta7978 Posted - 4 days ago

$ZNTL

User Image cta7978 Posted - 4 days ago

$ZNTL

User Image cta7978 Posted - 4 days ago

$ZNTL

User Image ZenInvestorZR Posted - 4 days ago

$ZNTL 2.9$ and then 2.6 $ ?

User Image zamun Posted - 4 days ago

$ZNTL typical pump and dump lol

User Image cta7978 Posted - 4 days ago

$ZNTL oh I see now these MFs promised us a corporate event by end of quarter, said they were on track… now delayed to January. Why sit on good news??

User Image Sillyspuh Posted - 4 days ago

$ZNTL fears swirling that RFK appointment will result in a lot of FDA quits, slowing down drug approval process; companies like Zentalis on a tight timeline can’t afford (literally) any delays

User Image First_Class_Seaman Posted - 6 days ago

$ZONE This will do a moonshot $ZNTL watching $EOSE im buying this. Chart about to go up.

User Image cta7978 Posted - 1 week ago

$ZNTL Really quite a flush $4.44 yesterday morning to $3.36.

User Image Sillyspuh Posted - 1 week ago

$ZNTL the RFK effect

User Image Sillyspuh Posted - 1 week ago

$ZNTL citadel/Ken Griffin ownership posted yesterday: https://ir.zentalis.com/static-files/9d7e6302-7996-43a5-88ca-6cc250944af3

User Image Gaben Posted - 1 week ago

$ZNTL

User Image AnomalyDetective Posted - 1 week ago

$ZNTL Week 46 MDA pick up another 7.8% premarket and +54.3% from November 1st signal on www.vmbreakouts.com Weekly MDA picks for members up +266.7% YTD in simulated portfolio adding 4 weekly picks average cumulative returns each week for the past 7+ years. https://seekingalpha.com/mp/1201-value-momentum-breakouts/subscribe

User Image Sillyspuh Posted - 1 week ago

$ZNTL with the latest update using language of registrational studies (= phase 3) it seems they’ve seen some data and it is good

User Image cta7978 Posted - 1 week ago

$ZNTL Gee can they take it negative now?

User Image apatbeck79 Posted - 1 week ago

$ZNTL well that was unexpected news so I bought 9k for fun

User Image cta7978 Posted - 1 week ago

$ZNTL New CEO led the buyout of Harpoon by Merck

User Image lucabrix Posted - 1 week ago

$ZNTL IMO this stock can make a great recover!

Analyst Ratings
Oppenheimer Outperform Sep 16, 24
Wedbush Neutral Aug 12, 24
HC Wainwright & Co. Buy Aug 12, 24
UBS Neutral Jun 20, 24
Wells Fargo Equal-Weight Jun 18, 24
Stifel Buy Jun 18, 24
HC Wainwright & Co. Buy Jun 18, 24
Oppenheimer Outperform Jun 18, 24
Morgan Stanley Equal-Weight Jun 18, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Lackner Mark Chief Scientific Off.. Chief Scientific Officer Feb 01 Sell 11.54 1,585 18,291 195,728 02/05/24
Paul Andrea Chief Legal Officer Chief Legal Officer Feb 01 Sell 11.54 3,310 38,197 149,973 02/05/24
Gallagher Cam President President Feb 01 Sell 11.54 11,552 133,310 644,450 02/05/24
Epperly Melissa B, Chief Financial Offi.. Chief Financial Officer Feb 01 Sell 11.54 8,669 100,040 454,022 02/05/24
Johnson David Michael Director Director Nov 10 Buy 9.879 17,000 167,943 144,389 11/13/23
Blackwell Kimberly Chief Executive Offi.. Chief Executive Officer Nov 13 Buy 10.2896 5,000 51,448 254,800 11/13/23
Brownstein Carrie Chief Medical Office.. Chief Medical Officer Oct 04 Sell 19.67 10,628 209,053 105,685 10/06/23
Bunker Kevin D. Chief Scientific Off.. Chief Scientific Officer Oct 04 Sell 19.67 6,068 119,358 859,089 10/06/23
Epperly Melissa B, Chief Financial Offi.. Chief Financial Officer Oct 04 Sell 19.67 5,482 107,831 387,691 10/06/23
Gallagher Cam President President May 31 Sell 26.3 27,768 730,298 463,502 05/31/23
Bunker Kevin D. Chief Scientific Off.. Chief Scientific Officer May 26 Sell 30.0156 80,000 2,401,248 15,000 05/31/23
Epperly Melissa B, Chief Financial Offi.. Chief Financial Officer Feb 13 Sell 20.2 7,851 158,590 392,048 02/14/23
Gallagher Cam President President Feb 13 Sell 20.19 11,833 238,908 491,270 02/14/23
Bunker Kevin D. Chief Scientific Off.. Chief Scientific Officer Feb 13 Sell 20.2 10,307 208,201 865,157 02/14/23
Gallagher Cam President President Feb 06 Sell 22.63 10,000 226,300 503,103 02/06/23
Gallagher Cam President President Jan 17 Sell 24.49 10,000 244,900 352,011 01/18/23
Gallagher Cam President President Nov 15 Sell 23.1 12,500 288,750 372,011 11/15/22
Gallagher Cam President President Nov 07 Sell 23.82 24,874 592,499 384,511 11/08/22
Gallagher Cam President President Oct 17 Sell 23.5103 12,500 293,879 409,385 10/17/22
Gallagher Cam President President Sep 15 Sell 25.01 22,500 562,725 444,385 09/16/22
Bunker Kevin D. Chief Operating Offi.. Chief Operating Officer Jul 20 Sell 30 5,000 150,000 100,000 07/20/22
Bunker Kevin D. Chief Operating Offi.. Chief Operating Officer Jul 13 Sell 30.02 5,000 150,100 105,000 07/14/22
Bunker Kevin D. Chief Operating Offi.. Chief Operating Officer Apr 11 Sell 31.98 5,000 159,900 135,000 04/13/22
Epperly Melissa B, Chief Financial Offi.. Chief Financial Officer Apr 04 Sell 50.75 17,080 866,810 247,414 04/05/22
SUN ANTHONY Y President & CEO President & CEO Apr 04 Sell 50.65 20,942 1,060,712 1,175,589 04/05/22
Gallagher Cam Director Director Apr 05 Sell 51.17 10,000 511,700 355,813 04/05/22
Bunker Kevin D. Chief Operating Offi.. Chief Operating Officer Mar 21 Sell 49.11 10,000 491,100 140,000 03/21/22
Gallagher Cam Director Director Mar 15 Sell 42.31 10,000 423,100 365,813 03/16/22
Bunker Kevin D. Chief Operating Offi.. Chief Operating Officer Mar 10 Sell 47.13 10,000 471,300 150,000 03/10/22
Gallagher Cam Director Director Mar 07 Sell 45.23 10,000 452,300 375,813 03/08/22
SUN ANTHONY Y President & CEO President & CEO Mar 01 Sell 50.2 20,942 1,051,288 1,196,531 03/03/22
Bunker Kevin D. Chief Operating Offi.. Chief Operating Officer Feb 22 Sell 49.08 10,000 490,800 160,000 02/23/22
Epperly Melissa B, Chief Financial Offi.. Chief Financial Officer Feb 23 Sell 49.2 1,913 94,120 264,494 02/23/22
Gallagher Cam Director Director Feb 15 Sell 52.04 10,000 520,400 385,813 02/15/22
Bunker Kevin D. Chief Operating Offi.. Chief Operating Officer Feb 10 Sell 52.24 14,688 767,301 764,110 02/14/22
Voliotis Dimitris SVP, Clinical Develo.. SVP, Clinical Development Feb 10 Sell 50.46 601 30,326 15,978 02/14/22
Pinto Alexis Chief Legal Officer Chief Legal Officer Feb 10 Sell 50.46 691 34,868 22,240 02/14/22
Gallagher Cam Director Director Feb 10 Sell 50.36 7,188 361,988 395,813 02/14/22
SUN ANTHONY Y President & CEO President & CEO Feb 10 Sell 50.46 4,733 238,827 1,217,473 02/14/22
Gallagher Cam Director Director Feb 07 Sell 53.55 10,000 535,500 387,203 02/07/22
SUN ANTHONY Y President & CEO President & CEO Feb 01 Sell 58.08 20,942 1,216,311 1,171,775 02/03/22
Voliotis Dimitris SVP, Clinical Develo.. SVP, Clinical Development Jan 18 Option 18 30,000 540,000 16,250 01/20/22
Voliotis Dimitris SVP, Clinical Develo.. SVP, Clinical Development Jan 18 Sell 62.02 30,000 1,860,600 6,250 01/20/22
Bunker Kevin D. Chief Operating Offi.. Chief Operating Officer Jan 20 Sell 60.22 10,000 602,200 180,000 01/20/22
Gallagher Cam Director Director Jan 18 Sell 63.05 10,000 630,500 397,203 01/19/22
Bunker Kevin D. Chief Operating Offi.. Chief Operating Officer Jan 10 Sell 68.58 10,000 685,800 190,000 01/11/22
SUN ANTHONY Y President & CEO President & CEO Jan 03 Sell 80.15 20,942 1,678,501 1,192,717 01/05/22
Bunker Kevin D. Chief Operating Offi.. Chief Operating Officer Dec 20 Sell 79.13 10,000 791,300 200,000 12/21/21
Bunker Kevin D. Chief Operating Offi.. Chief Operating Officer Dec 10 Sell 71.83 10,000 718,300 210,000 12/13/21
SUN ANTHONY Y President & CEO President & CEO Dec 01 Sell 76.76 20,942 1,607,508 1,103,659 12/02/21